About three million Americans have chronic Hepatitis C, a liver disease thats the most common condition leading to liver transplantation in the US Although Hepatitis C is treatable, the standard 48-week therapy only cures about 40% of patients, and its side effects are notoriously brutal and very difficult for many patients to endure. But a new Duke University Medical Center study finds adding a new anti-viral drug to the standard therapy can cut the length of the treatment regimen in half …